Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment. for metabolic syndrome

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Apr 2025: Trial registered, NCT06908473
  2. 24 Apr 2025: Trial started, NCT06908473

The trials

NCT06908473: Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients

State
Under way
Phase
Phase 3
People
530 planned
Started
24 Apr 2025
Primary completion
31 Jul 2028
Arms
Experimental Group (Tongmai Jiangtang Capsule Group)
Results
None posted
  1. 3 Apr 2025: Trial registered
  2. 24 Apr 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.